Physician profile
Keivan Ettefagh
NPI 1144227729
$1,801.58
in general payments reported to CMS, 2019-2025
23 companies · $418 in 2025
The $418 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $142 · 2021: $175 · 2022: $207 · 2023: $232 · 2024: $460 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $386.82 | 2019-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $259.63 | 2019-2025 | Bexsero, Pediarix |
| Sanofi-Aventis U.S. LLC | $234.27 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $129.19 | 2020-2024 | |
| Corium, LLC | $97.28 | 2022-2024 | Azstarys |
| Cranial Technologies, INC | $93.03 | 2019-2025 | Doc Band |
| Kaleo, INC. | $89.31 | 2019-2023 | Auvi-Q |
| Supernus Pharmaceuticals, INC. | $80.95 | 2021-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $75.27 | 2020-2024 | Vaxneuvance, Vaqta, Gardasil 9 |
| Alk-Abello, INC | $56.24 | 2023-2025 | Neffy, Odactra, Ragwitek |
| Biomarin Pharmaceutical INC. | $51.46 | 2023-2025 | Voxzogo 1.2mg |
| Sobi, INC | $43.29 | 2019-2021 | |
| Pfizer INC. | $42.58 | 2024-2025 | |
| Baxter Healthcare | $24.52 | 2022 | |
| Adlon Therapeutics L.P. | $19.45 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $17.96 | 2022 | |
| Acadia Pharmaceuticals INC | $17.88 | 2024 | Daybue |
| Collegium Pharmaceutical, INC. | $16.08 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $14.87 | 2024 | Ycanth |
| Sanofi Pasteur INC. | $14.45 | 2025 | |
| Amneal Pharmaceuticals LLC | $13.19 | 2019 | |
| Biogen, INC. | $12.68 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keivan Ettefagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.